FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Diabetes is one of the most common chronic diseases which is encountered in our day to day life. Patients with diabetes ...

KHOU 11 News anchor Rekha Muddaraj spoke to an endocrinologist with UT Physicians about the chronic disease and what to look ...

New data shows that men are still more likely than women to be diagnosed with diabetes in the U.S., rates of the disease have ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Because November is Diabetes and Alzheimer’s awareness month, we are learning about the link between brain health and insulin ...

Thursday is World Diabetes Day. The goal is to raise awareness of the daily challenges millions face with the disease.

Diabetes is one of the most common chronic illnesses impacting daily lives. Medically, diabetes is classified into two ...

World Diabetes Day, observed annually on November 14th, raises awareness about the escalating global diabetes epidemic. The ...